Publication at Faculty of Medicine in Pilsen |
2023
Abstract
Small cell lung cancers are among cancer diseases in which treatment outcomes have improved very little during the previous decades. ln recent years, however, there has been some improvement in early as well as long-term treatment outcomes in patients with extensive-stage disease. Clinical trials using the combination of standard chemotherapy of etoposide and a platinum derivative with durvalumab, atezolizumab, and pembrolizumab have yielded positive results.
The results of tria I s mentioned here which focused on epigenetic changes in tumour tissue and on investigating gene expression profiles hold promíse in terms of possible personalization of systemic therapy.